Plus   Neg

Stock Alert: Mesoblast Tanks 30%

Shares of Mesoblast Ltd. (MESO) are down over 30% on Tuesday morning after the U.S. FDA released two advisory reports related to Ryoncil, a stem cell treatment for children with a specific inflammatory condition. An FDA panel is slated to review Ryoncil on August 13, 2020.

Mesoblast is seeking Biologics License Application for approval of Ryoncil (remestemcel-L) in the treatment of steroid-refractory acute graft versus host disease in children.

There are currently no FDA-approved treatments in the US for children under 12 with SR-aGVHD, a potentially life-threatening complication of an allogeneic bone marrow transplant for blood cancer.

The FDA's oncologic drugs advisory committee briefings conclude it is unclear whether clinical trial results submitted provide evidence of sufficient benefit in the treatment of SR-aGVHD.

FDA's ODAC will meet on Thursday to consider evidence of the effectiveness of Ryoncil.

"FDA's position is that the product attributes the Applicant has identified as related to potency and activity do not have a demonstrated relationship to the clinical performance of specific [drug protocol] lots, and that the product's proposed immunomodulatory mechanism of action has not been demonstrated in vivo in study subjects receiving remestemcel-L," the briefing paper noted.

MESO is currently trading at $12.03, down $5.39 or 30.94%, on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
British retailer Arcadia fashion group, owned by Philip Green, has entered into administration as it seeks protection from creditors following significant business loss during the coronavirus pandemic. The administration is likely to affect around its 13,000 employees. The retailer, which owns eight high street and fashion retails brands, is now seeking buyers for its brands. Data giant S&P Global Inc. has agreed to acquire information and analytics company IHS Markit Ltd. in an all-stock deal, the two companies said Monday. The deal values IHS Markit at an enterprise value of $44 billion, including $4.8 billion of net debt. Shares of IHS Markit are gaining almost 6 percent following the news. The deal is the biggest in 2020. Moderna, Inc. (MRNA) said it will apply for an Emergency Use approval of its Covid vaccine as the latest study showed that the vaccine candidate is 94.1% effective to prevent Covid-19. The company said there have been no serious safety concerns identified. The company will file for an Emergency...
Follow RTT